Freeman Hospital
Welcome,         Profile    Billing    Logout  
 59 Trials 
781 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jackson, Graham
Myeloma XI, NCT01554852 / 2009-010956-93: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Checkmark From P3 Myeloma XI trial in NDDM at ASH 2016
Dec 2016 - Dec 2016: From P3 Myeloma XI trial in NDDM at ASH 2016
Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Active, not recruiting
3
4420
Europe
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen
Multiple Myeloma
12/21
12/22
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
Wasan, Harpreet S
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
SIRCCA, NCT02807181: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Completed
2/3
89
Europe, US, RoW
Cisplatin-gemcitabine, CIS-GEM, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sirtex Medical
Intrahepatic Cholangiocarcinoma
10/22
10/22
CUPem, NCT03752333 / 2018-001327-39: Trial of Pembrolizumab in Cancer of Unknown Primary

Active, not recruiting
2
77
Europe
Pembrolizumab, Keytruda
Imperial College London, Merck Sharp & Dohme LLC
Cancer of Unknown Primary Site
03/24
09/24
NCT04362449: Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Recruiting
2
30
Europe
Shortened hydration time and dispensary of Akynzeo, Standard of care
Imperial College Healthcare NHS Trust, Chugai Pharma UK Limited
Gallbladder Cancer
02/23
02/23
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/25
09/25
PRIMUS 001, NCT04151277 / ISRCTN75002153 / 2016-004155-67: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

Recruiting
2
500
Europe
FOLFOX-A, Gemcitabe and Abraxane, G-CSF
Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow
Neoplasms Pancreatic
12/25
01/26
OSPREY, NCT04493632: is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Recruiting
N/A
500
Europe
OncoSil Medical Limited
Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasm, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
11/25
10/27
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Recruiting
N/A
2500
Europe
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde
Neoplasms Pancreatic
12/25
12/25
Plummer, Ruth
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
MIV-818-101, NCT03781934 / 2018-000995-14: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations

Active, not recruiting
1/2
53
Europe, RoW
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Medivir
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
01/25
06/25
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Active, not recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
08/25
08/25
NCT03892018: The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Terminated
1
29
Europe
Oraxol, Paclitaxel and HM30181AK-US
Athenex, Inc.
Solid Tumor, Adult
05/23
05/23
NCT03447470 / 2017-000720-98: Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Completed
1
46
Europe
RXC004, Nivolumab
Redx Pharma Ltd
Cancer, Solid Tumor
09/23
09/23
ACT, NCT04021277: PS101-mediated With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

Terminated
1
11
Europe
20 uL/kg PS101, 40 uL/kg PS101, Ultrasound
EXACT Therapeutics AS
Solid Tumor, Colorectal Cancer
08/24
09/24
Nair, Arun
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
Lidsky, Karen
ASCEND, NCT05388708: ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment

Recruiting
N/A
550
Europe, Canada, US, RoW
ECMO support, PROSpect protocolized therapies
University of Michigan, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
09/27
09/27
Gruberg, Luis
MINT, NCT02981407: Myocardial Ischemia and Transfusion

Completed
3
3506
Europe, Canada, US, RoW
Red Blood Cell Transfusion
Rutgers, The State University of New Jersey, University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Infarction, Anemia
05/23
10/23
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting
N/A
3100
Europe, US, RoW
Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent
Medstar Health Research Institute
Atherosclerosis
04/27
08/27
Vogiatzis, Ioannis
MINOCA-GR, NCT04186676: Myocardial Infarction With Non-Obstructive Coronary Arteries in the Greek Population

Completed
N/A
60
Europe
MINOCA registry, CCTA Phenotypes
AHEPA University Hospital, New York University, University of Zurich
Acute Myocardial Infarction, Non-Obstructive Coronary Atherosclerosis, Ischemic Heart Disease, Angina Pectoris, Coronary Microvascular Disease
01/24
01/24
MacGowan, Guy A
NCT05416879: Lifestyle Behaviours of Women Newly Diagnosed With Heart Failure

Recruiting
N/A
40
Europe
Actigraph GT3X+BT
Newcastle University
Heart Failure
06/26
06/26
Kunadian, Vijay
SENIOR-RITA, NCT03052036: The British Heart Foundation Trial

Active, not recruiting
N/A
1518
Europe
Coronary Angiography, Coronary revascularisation, Optimal Medical Therapy
Newcastle-upon-Tyne Hospitals NHS Trust, British Heart Foundation, Newcastle University
NSTEMI - Non-ST Segment Elevation MI
03/24
06/29
EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock

Recruiting
N/A
428
Europe
Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation.
University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC)
Cardiogenic Shock
03/23
02/24
Clark, Stephen
NCT03991923: Non-ischemic Preservation of the Donor Heart in Heart Transplantation

Active, not recruiting
N/A
230
Europe
XVIVO heart preservation devices, Standard ICSS
XVIVO Perfusion
Heart Transplantation
08/23
12/28
PIVOTAL, NCT05547165: Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting
N/A
240
US
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Nationwide Children's Hospital, National Institutes of Health (NIH), Abbott, University of Pittsburgh, University of Bristol, Dartmouth College, University of Iowa, Emory University, Cedars-Sinai Medical Center, Children's Hospital Los Angeles, National Heart, Lung, and Blood Institute (NHLBI)
Ductus Arteriosus, Patent
02/26
02/26
Greystoke, Alastair
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
CRUKD/22/002, NCT05057013: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Recruiting
1/2
81
Europe
HMBD-001, HMBD-001 and enzalutamide
Cancer Research UK, Hummingbird Bioscience
Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck
09/26
09/26
CONCORDE, NCT04550104: A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Recruiting
1
200
Europe
Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD2281, AZD1390, Ceralasertib, AZD6738, AZD5305, Durvalumab
University of Leeds, University of Manchester, Newcastle University, University of Oxford, The Leeds Teaching Hospitals NHS Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Velindre NHS Trust, University College London Hospitals, Queen's University, Belfast, University of Sheffield
Non Small Cell Lung Cancer
03/26
03/28
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
TARGET National, NCT04723316: Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting
N/A
6000
Europe
The Christie NHS Foundation Trust
Cancer
01/26
01/28
Ross, Paul
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/25
09/25
PRIMER-1, NCT05185739: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

Recruiting
2
60
Europe
Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib
University College, London, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
07/28
07/30
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Recruiting
N/A
1000
Europe
Royal Marsden NHS Foundation Trust
Colorectal Cancer
07/29
07/31
OSPREY, NCT04493632: is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Recruiting
N/A
500
Europe
OncoSil Medical Limited
Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasm, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
11/25
10/27
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
Prentis, James
NCT05260567: Telehealth Exercise Training in Peripheral Arterial Disease - TEXT-PAD

Completed
N/A
60
Europe
Exercise and Lifestyle Change
Northumbria University
Peripheral Arterial Disease, Intermittent Claudication, Behavior, Health, Exercise Intervention
07/23
11/23
Wright, Stephen
NCT05582044: Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction

Recruiting
N/A
60
Canada
Lower-body Negative Pressure (-25 mmHg), Lower-body Negative Pressure (-15 mmHg), Lower-body Neutral Pressure (0 mmHg)
University of British Columbia
Heart Failure With Preserved Ejection Fraction
01/26
01/26
Bagnall, Alan
P4, NCT05253677: Precise Procedural and PCI Plan

Recruiting
N/A
1000
Europe
CT-guided PCI, IVUS-guided PCI
CoreAalst BV
Coronary Artery Disease
12/24
10/26
GPS Registry, NCT05027685: The "Global Paradise System" Registry

Recruiting
N/A
3000
Europe, RoW
The Paradise Ultrasound Renal Denervation System
ReCor Medical, Inc.
Hypertension
12/30
12/31
Egred, Mohaned
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting
N/A
3100
Europe, US, RoW
Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent
Medstar Health Research Institute
Atherosclerosis
04/27
08/27
Lewis, Joanne
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma

Active, not recruiting
2/3
140
Europe, RoW
LAM561, TMZ, RT
Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS
Primary Glioblastoma, Glioblastoma Multiforme
10/24
05/25
NCT04359745: Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression

Recruiting
N/A
500
Europe
Guy's and St Thomas' NHS Foundation Trust, King's College London
Glioblastoma
05/24
05/25
NCT04274283: Tessa Jowell BRAIN MATRIX - Platform Study

Recruiting
N/A
1000
Europe
Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
University of Birmingham, The Brain Tumour Charity, University of Oxford, University of Edinburgh, Genomics England
Glioma
03/26
03/27
Plummer, Elizabeth R
ELUCIDATE, NCT05985655: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors

Recruiting
1/2
170
Europe
GTAEXS617
Exscientia AI Limited, GT Apeiron LLC
Advanced Solid Tumor
01/28
05/28
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Zaman, Azfar
NCT06412250: A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)

Recruiting
N/A
2000
Europe, RoW
Translumina Therapeutics LLP, Iqvia Pty Ltd
Cardiovascular Diseases
05/26
05/26
ZODIAC, NCT05844566: OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

Completed
N/A
1139
Europe
Decision Support System (DSS)
Imperial College London, Sanofi, Axtria, Inc., Hospital Universitario La Paz, Hippocrates Research
Acute Coronary Syndrome, Myocardial Infarction
12/24
12/24
NCT04390672: Multivessel TALENT

Active, not recruiting
N/A
1550
Europe
SUPRAFLEX Cruz, SYNERGY
National University of Ireland, Galway, Ireland
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arterial Occlusive Diseases, Vascular Diseases
09/25
09/26
OPTIMAL, NCT04111770: The Randomized Controlled Trial

Active, not recruiting
N/A
807
Europe
IVUS guided Percutaneous Coronary Intervention, QCA guided Percutaneous Coronary Intervention
ECRI bv, Philips Healthcare, Boston Scientific Corporation
Left Main Coronary Artery Stenosis
07/25
07/25
Loebinger, Michael
CLEAR, NCT04140214 / 2017-000664-14: Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis

Completed
3
288
Europe
Hypertonic saline, MucoClear 6%, HTS, Carbocysteine 750 MG, Mucodyne
Belfast Health and Social Care Trust, Queen's University, Belfast
Bronchiectasis
09/24
12/24
VitalBE, NCT03696290 / 2018-001590-24: Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Recruiting
2
77
Europe
Aztreonam lysine, Cayston, Placebo, Lactose monohydrate
University of Dundee, Gilead Sciences
Bronchiectasis Adult
09/25
09/25
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting
1/2
45
Europe
CHF6333, CHF6333 Placebo
Chiesi Farmaceutici S.p.A.
Bronchiectasis
06/25
06/25
NCT06600425: A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

Active, not recruiting
1
10
Europe
RCT1100
ReCode Therapeutics
Primary Ciliary Dyskinesia
06/25
09/25
Patel, Bijal
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Recruiting
3
153
Europe, Canada, US, RoW
Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod
AiCuris Anti-infective Cures AG, Medpace, Inc.
HSV Infection
07/25
11/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting
2
494
Europe
Capecitabine, MEDI4736 (Durvalumab), Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
NCT04440735: A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Active, not recruiting
1/2
125
US
DSP107, Atezolizumab
Kahr Medical
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
09/25
09/25
NCT03840460: A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Recruiting
N/A
200
Europe
Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma
01/23
01/23
Torres, Paulo
AMARTA, NCT05741983: AMIC vs. MFx in the Ankle

Withdrawn
N/A
110
Europe
Microfracture (MFx), Chondro-Gide®
Geistlich Pharma AG
Osteochondral Lesion of Talus, Chondral Defect, Microfracture
02/24
02/24
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
TAK-665-4001, NCT05058391 / 2022-004193-39: A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed
4
5
RoW
Elaprase, Idursulfase
Takeda, Takeda Biopharmaceuticals India Pvt. Ltd.
Hunter Syndrome
04/24
04/24
NCT06831370: A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting
4
124
RoW
Brentuximab Vedotin, Adcetris, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine
Takeda
Hodgkin Lymphoma
03/26
03/26
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Recruiting
4
78
US
Fruquintinib, Fruzaqla™
Takeda
Colorectal Cancer
10/27
10/27
PANORAMA, NCT06581328: A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Recruiting
4
400
US
Vedolizumab IV, Entyvio, Vedolizumab SC
Takeda
Ulcerative Colitis, Crohn's Disease
10/27
06/28
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Terminated
4
53
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
02/25
02/25
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
52
Europe, Japan, US
TAK-755, rADAMTS13, SHP-655, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
SWOG-S1600, NCT03757949: Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Active, not recruiting
3
203
US
Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Bladder Carcinoma
01/24
01/27
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
3
206
Canada, US
Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS)
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology
Brain Metastases
06/27
12/27
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Completed
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
01/25
01/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jackson, Graham
Myeloma XI, NCT01554852 / 2009-010956-93: Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

Checkmark From P3 Myeloma XI trial in NDDM at ASH 2016
Dec 2016 - Dec 2016: From P3 Myeloma XI trial in NDDM at ASH 2016
Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Active, not recruiting
3
4420
Europe
Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Revlimid (lenalidomide), Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen, Kyprolis (carfilzomib), Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen, Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen, Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen, Velcade (bortezomib), Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance, Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance, Zolinza (vorinostat), High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)
University of Leeds, Celgene, Merck Sharp & Dohme LLC, Amgen
Multiple Myeloma
12/21
12/22
FiTNEss, NCT03720041 / 2018-003590-10: Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma

Recruiting
3
740
Europe
R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance
University of Leeds, Cancer Research UK, Takeda, Celgene
Multiple Myeloma
12/24
12/24
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII

Recruiting
3
406
Europe
Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy
University of Leeds, Cancer Research UK, Takeda
Multiple Myeloma
03/26
03/27
Wasan, Harpreet S
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
SIRCCA, NCT02807181: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Completed
2/3
89
Europe, US, RoW
Cisplatin-gemcitabine, CIS-GEM, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sirtex Medical
Intrahepatic Cholangiocarcinoma
10/22
10/22
CUPem, NCT03752333 / 2018-001327-39: Trial of Pembrolizumab in Cancer of Unknown Primary

Active, not recruiting
2
77
Europe
Pembrolizumab, Keytruda
Imperial College London, Merck Sharp & Dohme LLC
Cancer of Unknown Primary Site
03/24
09/24
NCT04362449: Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration

Recruiting
2
30
Europe
Shortened hydration time and dispensary of Akynzeo, Standard of care
Imperial College Healthcare NHS Trust, Chugai Pharma UK Limited
Gallbladder Cancer
02/23
02/23
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/25
09/25
PRIMUS 001, NCT04151277 / ISRCTN75002153 / 2016-004155-67: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer

Recruiting
2
500
Europe
FOLFOX-A, Gemcitabe and Abraxane, G-CSF
Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow
Neoplasms Pancreatic
12/25
01/26
OSPREY, NCT04493632: is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Recruiting
N/A
500
Europe
OncoSil Medical Limited
Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasm, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
11/25
10/27
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

Recruiting
N/A
2500
Europe
Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling
Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde
Neoplasms Pancreatic
12/25
12/25
Plummer, Ruth
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
NCT04785365: Long-Term Follow-Up Study of Patients Receiving ATL001

Terminated
2
1
Europe
Biological: ATL001
Achilles Therapeutics UK Limited
Melanoma, Advanced Non Small Cell Lung Cancer
10/23
10/23
MIV-818-101, NCT03781934 / 2018-000995-14: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations

Active, not recruiting
1/2
53
Europe, RoW
MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib
Medivir
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
01/25
06/25
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Active, not recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
08/25
08/25
NCT03892018: The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol

Terminated
1
29
Europe
Oraxol, Paclitaxel and HM30181AK-US
Athenex, Inc.
Solid Tumor, Adult
05/23
05/23
NCT03447470 / 2017-000720-98: Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

Completed
1
46
Europe
RXC004, Nivolumab
Redx Pharma Ltd
Cancer, Solid Tumor
09/23
09/23
ACT, NCT04021277: PS101-mediated With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

Terminated
1
11
Europe
20 uL/kg PS101, 40 uL/kg PS101, Ultrasound
EXACT Therapeutics AS
Solid Tumor, Colorectal Cancer
08/24
09/24
Nair, Arun
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
Lidsky, Karen
ASCEND, NCT05388708: ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment

Recruiting
N/A
550
Europe, Canada, US, RoW
ECMO support, PROSpect protocolized therapies
University of Michigan, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
09/27
09/27
Gruberg, Luis
MINT, NCT02981407: Myocardial Ischemia and Transfusion

Completed
3
3506
Europe, Canada, US, RoW
Red Blood Cell Transfusion
Rutgers, The State University of New Jersey, University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Infarction, Anemia
05/23
10/23
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting
N/A
3100
Europe, US, RoW
Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent
Medstar Health Research Institute
Atherosclerosis
04/27
08/27
Vogiatzis, Ioannis
MINOCA-GR, NCT04186676: Myocardial Infarction With Non-Obstructive Coronary Arteries in the Greek Population

Completed
N/A
60
Europe
MINOCA registry, CCTA Phenotypes
AHEPA University Hospital, New York University, University of Zurich
Acute Myocardial Infarction, Non-Obstructive Coronary Atherosclerosis, Ischemic Heart Disease, Angina Pectoris, Coronary Microvascular Disease
01/24
01/24
MacGowan, Guy A
NCT05416879: Lifestyle Behaviours of Women Newly Diagnosed With Heart Failure

Recruiting
N/A
40
Europe
Actigraph GT3X+BT
Newcastle University
Heart Failure
06/26
06/26
Kunadian, Vijay
SENIOR-RITA, NCT03052036: The British Heart Foundation Trial

Active, not recruiting
N/A
1518
Europe
Coronary Angiography, Coronary revascularisation, Optimal Medical Therapy
Newcastle-upon-Tyne Hospitals NHS Trust, British Heart Foundation, Newcastle University
NSTEMI - Non-ST Segment Elevation MI
03/24
06/29
EUROSHOCK, NCT03813134: Testing the Value of Novel Strategy and Its Cost Efficacy in Order to Improve the Poor Outcomes in Cardiogenic Shock

Recruiting
N/A
428
Europe
Percutaneous coronary intervention (PCI), Pharmacological Support, VA-ECMO, Veno-Arterial Extra Corporeal Membrane Oxygenation.
University of Leicester, European Commission, University of Glasgow, KU Leuven, University of East Anglia, Deutsches Herzzentrum Muenchen, A.O. Ospedale Papa Giovanni XXIII, Chalice Medical Ltd, Ludwig-Maximilians - University of Munich, University of Tromso, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Paula Stradina Liniska Universitates, Accelopment AG, Universiteit Antwerpen, Cardiovascular European Research Centre (CERC)
Cardiogenic Shock
03/23
02/24
Clark, Stephen
NCT03991923: Non-ischemic Preservation of the Donor Heart in Heart Transplantation

Active, not recruiting
N/A
230
Europe
XVIVO heart preservation devices, Standard ICSS
XVIVO Perfusion
Heart Transplantation
08/23
12/28
PIVOTAL, NCT05547165: Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Recruiting
N/A
240
US
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Nationwide Children's Hospital, National Institutes of Health (NIH), Abbott, University of Pittsburgh, University of Bristol, Dartmouth College, University of Iowa, Emory University, Cedars-Sinai Medical Center, Children's Hospital Los Angeles, National Heart, Lung, and Blood Institute (NHLBI)
Ductus Arteriosus, Patent
02/26
02/26
Greystoke, Alastair
DETERMINE, NCT05768178: Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Recruiting
2/3
30
Europe
Vemurafenib, Zelboraf, Cobimetinib, Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms, Colorectal Neoplasms, Laryngeal Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioma, Multiple Myeloma, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic
10/29
10/29
CRUKD/21/004, NCT05722886: DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05786716: Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations

Recruiting
2/3
30
Europe
Trastuzumab, Herceptin, Pertuzumab, Perjeta
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms, Salivary Gland Neoplasm, Lung Neoplasm, Pancreatic Neoplasm, Ovarian Neoplasms, Prostatic Neoplasm, Skin Neoplasm
10/29
10/29
DETERMINE, NCT05770102: Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Recruiting
2/3
30
Europe
Atezolizumab, Tecentriq
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Colorectal Neoplasms, Endometrial Neoplasms, Melanoma
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
DETERMINE, NCT05770544: Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.

Recruiting
2/3
30
Europe
Entrectinib, Rozlytrek
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Brain Neoplasms, Melanoma, Glioma
10/29
10/29
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
CRUKD/22/002, NCT05057013: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Recruiting
1/2
81
Europe
HMBD-001, HMBD-001 and enzalutamide
Cancer Research UK, Hummingbird Bioscience
Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck
09/26
09/26
CONCORDE, NCT04550104: A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Recruiting
1
200
Europe
Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD2281, AZD1390, Ceralasertib, AZD6738, AZD5305, Durvalumab
University of Leeds, University of Manchester, Newcastle University, University of Oxford, The Leeds Teaching Hospitals NHS Trust, Beatson West of Scotland Cancer Centre, University of Glasgow, Velindre NHS Trust, University College London Hospitals, Queen's University, Belfast, University of Sheffield
Non Small Cell Lung Cancer
03/26
03/28
FRAME, NCT03875820: Phase I Trial of Defactinib and VS-6766.

Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Sep 2021 - Sep 2021: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer at ESMO 2021
Checkmark Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Sep 2020 - Sep 2020: Data from FRAME trial in combination with VS-6766 for Ovarian Cancer
Checkmark Data from FRAME trial in combination with VS-6766 for solid tumors at AACR 2020
More
Active, not recruiting
1
87
Europe
VS-6766, RO5126766, CH5126766, Defactinib, VS-6063
Institute of Cancer Research, United Kingdom, Verastem, Inc.
NSCLC, Low Grade Serous Ovarian Cancer, Endometrioid Carcinoma, Pancreatic Cancer
04/23
10/23
KisMET-01, NCT05652868: Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting
1
250
Europe, US, RoW
MYTX-011
Mythic Therapeutics
NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
12/25
12/27
TARGET National, NCT04723316: Tumour Characterisation to Guide Experimental Targeted Therapy - National

Recruiting
N/A
6000
Europe
The Christie NHS Foundation Trust
Cancer
01/26
01/28
Ross, Paul
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
TRIPP-FFX, NCT05466799: FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Recruiting
2
80
Europe, RoW
FOLFIRINOX chemotherapy, Folinic Acid, 5-FU, Oxaliplatin, Irinotecan, OncoSil™, Phosphorous-32 microparticles
OncoSil Medical Limited
Locally Advanced Pancreatic Cancer
06/25
09/25
PRIMER-1, NCT05185739: Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)

Recruiting
2
60
Europe
Pembrolizumab, Lenvatinib, Pembrolizumab and Lenvatinib
University College, London, Merck Sharp & Dohme LLC
Hepatocellular Carcinoma
07/28
07/30
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Recruiting
N/A
1000
Europe
Royal Marsden NHS Foundation Trust
Colorectal Cancer
07/29
07/31
OSPREY, NCT04493632: is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Recruiting
N/A
500
Europe
OncoSil Medical Limited
Pancreatic Neoplasm, Digestive System Neoplasm, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasm, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
11/25
10/27
SIRtain, NCT05967143: Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors ( Registry)

Recruiting
N/A
845
Europe
SIRT
Sirtex Medical
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
06/28
06/29
Prentis, James
NCT05260567: Telehealth Exercise Training in Peripheral Arterial Disease - TEXT-PAD

Completed
N/A
60
Europe
Exercise and Lifestyle Change
Northumbria University
Peripheral Arterial Disease, Intermittent Claudication, Behavior, Health, Exercise Intervention
07/23
11/23
Wright, Stephen
NCT05582044: Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction

Recruiting
N/A
60
Canada
Lower-body Negative Pressure (-25 mmHg), Lower-body Negative Pressure (-15 mmHg), Lower-body Neutral Pressure (0 mmHg)
University of British Columbia
Heart Failure With Preserved Ejection Fraction
01/26
01/26
Bagnall, Alan
P4, NCT05253677: Precise Procedural and PCI Plan

Recruiting
N/A
1000
Europe
CT-guided PCI, IVUS-guided PCI
CoreAalst BV
Coronary Artery Disease
12/24
10/26
GPS Registry, NCT05027685: The "Global Paradise System" Registry

Recruiting
N/A
3000
Europe, RoW
The Paradise Ultrasound Renal Denervation System
ReCor Medical, Inc.
Hypertension
12/30
12/31
Egred, Mohaned
NCT04221815: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Recruiting
N/A
3100
Europe, US, RoW
Eagle Eye Platinum digital IVUS catheter with optional SyncVision, Resolute Onyx Drug Eluting Stent, Onyx Frontier Drug Eluting Stent, Onyx TruStar Drug Eluting Stent, Onyx TruCor Drug Eluting Stent
Medstar Health Research Institute
Atherosclerosis
04/27
08/27
Lewis, Joanne
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
CLINGLIO, NCT04250922 / 2018-000365-37: LAM561 With RT and TMZ for Adults With Glioblastoma

Active, not recruiting
2/3
140
Europe, RoW
LAM561, TMZ, RT
Laminar Pharmaceuticals, Laboratory Corporation of America, Northern Institute for Cancer Research, Newcastle, Theradis pharma, LIPODOM THERAPEUTICS
Primary Glioblastoma, Glioblastoma Multiforme
10/24
05/25
NCT04359745: Improving Treatment of Glioblastoma: Distinguishing Progression From Pseudoprogression

Recruiting
N/A
500
Europe
Guy's and St Thomas' NHS Foundation Trust, King's College London
Glioblastoma
05/24
05/25
NCT04274283: Tessa Jowell BRAIN MATRIX - Platform Study

Recruiting
N/A
1000
Europe
Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
University of Birmingham, The Brain Tumour Charity, University of Oxford, University of Edinburgh, Genomics England
Glioma
03/26
03/27
Plummer, Elizabeth R
ELUCIDATE, NCT05985655: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors

Recruiting
1/2
170
Europe
GTAEXS617
Exscientia AI Limited, GT Apeiron LLC
Advanced Solid Tumor
01/28
05/28
DDRiver Solid Tumours 301, NCT04170153: Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Active, not recruiting
1
161
Europe, Japan, US, RoW
M1774, Tuvusertib, Niraparib
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Metastatic or Locally Advanced Unresectable Solid Tumors
01/26
01/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Zaman, Azfar
NCT06412250: A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry)

Recruiting
N/A
2000
Europe, RoW
Translumina Therapeutics LLP, Iqvia Pty Ltd
Cardiovascular Diseases
05/26
05/26
ZODIAC, NCT05844566: OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.

Completed
N/A
1139
Europe
Decision Support System (DSS)
Imperial College London, Sanofi, Axtria, Inc., Hospital Universitario La Paz, Hippocrates Research
Acute Coronary Syndrome, Myocardial Infarction
12/24
12/24
NCT04390672: Multivessel TALENT

Active, not recruiting
N/A
1550
Europe
SUPRAFLEX Cruz, SYNERGY
National University of Ireland, Galway, Ireland
Coronary Artery Disease, Myocardial Ischemia, Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arterial Occlusive Diseases, Vascular Diseases
09/25
09/26
OPTIMAL, NCT04111770: The Randomized Controlled Trial

Active, not recruiting
N/A
807
Europe
IVUS guided Percutaneous Coronary Intervention, QCA guided Percutaneous Coronary Intervention
ECRI bv, Philips Healthcare, Boston Scientific Corporation
Left Main Coronary Artery Stenosis
07/25
07/25
Loebinger, Michael
CLEAR, NCT04140214 / 2017-000664-14: Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis

Completed
3
288
Europe
Hypertonic saline, MucoClear 6%, HTS, Carbocysteine 750 MG, Mucodyne
Belfast Health and Social Care Trust, Queen's University, Belfast
Bronchiectasis
09/24
12/24
VitalBE, NCT03696290 / 2018-001590-24: Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Recruiting
2
77
Europe
Aztreonam lysine, Cayston, Placebo, Lactose monohydrate
University of Dundee, Gilead Sciences
Bronchiectasis Adult
09/25
09/25
NCT06166056: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Recruiting
1/2
45
Europe
CHF6333, CHF6333 Placebo
Chiesi Farmaceutici S.p.A.
Bronchiectasis
06/25
06/25
NCT06600425: A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD

Active, not recruiting
1
10
Europe
RCT1100
ReCode Therapeutics
Primary Ciliary Dyskinesia
06/25
09/25
Patel, Bijal
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Recruiting
3
153
Europe, Canada, US, RoW
Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod
AiCuris Anti-infective Cures AG, Medpace, Inc.
HSV Infection
07/25
11/25
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis

Checkmark Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022
Hourglass Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis
Checkmark Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022
More
Recruiting
3
350
Europe, Canada, US, RoW
Selinexor, KPT-330, Placebo, Ruxolitinib
Karyopharm Therapeutics Inc
Myelofibrosis
09/25
03/28
PLATFORM, NCT02678182: Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Active, not recruiting
2
494
Europe
Capecitabine, MEDI4736 (Durvalumab), Trastuzumab, Rucaparib, Ramucirumab
Royal Marsden NHS Foundation Trust, MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
03/25
06/27
NCT04440735: A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Active, not recruiting
1/2
125
US
DSP107, Atezolizumab
Kahr Medical
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
09/25
09/25
NCT03840460: A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Recruiting
N/A
200
Europe
Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma
01/23
01/23
Torres, Paulo
AMARTA, NCT05741983: AMIC vs. MFx in the Ankle

Withdrawn
N/A
110
Europe
Microfracture (MFx), Chondro-Gide®
Geistlich Pharma AG
Osteochondral Lesion of Talus, Chondral Defect, Microfracture
02/24
02/24
Contact, Site Public
NCT04985682 / 2022-004149-11: A Study of ADVATE in People With Hemophilia A in India

Completed
4
50
RoW
ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Hemophilia A
02/23
02/23
SWITCH, NCT04718779: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

Completed
4
4
US
Digital Engagement Application (GD App), No Intervention
Takeda
Gaucher Disease
02/23
02/23
COMPASS-CD, NCT04809363: A Study of CDPATH™ to Help Manage and Treat Crohn's Disease

Active, not recruiting
4
200
US
CDPATH™, PROSPECT, Blood Draw
Takeda
Crohn's Disease
10/25
06/26
NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting
4
80
RoW
Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M
Takeda, Takeda
Central Precocious Puberty
05/25
05/25
TAK-665-4001, NCT05058391 / 2022-004193-39: A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Completed
4
5
RoW
Elaprase, Idursulfase
Takeda, Takeda Biopharmaceuticals India Pvt. Ltd.
Hunter Syndrome
04/24
04/24
NCT06831370: A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting
4
124
RoW
Brentuximab Vedotin, Adcetris, Doxorubicin, Adriamycin, Vinblastine, Dacarbazine
Takeda
Hodgkin Lymphoma
03/26
03/26
NCT05442554: A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Completed
4
10
RoW
Brentuximab vedotin, SGN-35
Takeda
T-Cell Lymphoma
08/24
08/24
NCT05067868: A Study of Replagal in Children and Adults With Fabry Disease in India

Active, not recruiting
4
5
RoW
Replagal
Shire
Fabry Disease
10/26
11/26
TAK-113-4002, NCT06562543: A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

Recruiting
4
78
US
Fruquintinib, Fruzaqla™
Takeda
Colorectal Cancer
10/27
10/27
PANORAMA, NCT06581328: A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Recruiting
4
400
US
Vedolizumab IV, Entyvio, Vedolizumab SC
Takeda
Ulcerative Colitis, Crohn's Disease
10/27
06/28
NCT04085172 / 2018-000821-29: A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Active, not recruiting
4
288
Europe, US
Guanfacine hydrochloride (TAK-503), Intuniv, SPD503, Atomoxetine hydrochloride, Placebo
Shire, Takeda Development Center Americas, Inc.
Attention Deficit Hyperactivity Disorder
06/27
06/27
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Terminated
4
53
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
02/25
02/25
NCT05494593: A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)

Recruiting
4
5
US
ELAPRASE, Idursulfase, Rituximab, Methotrexate, Intravenous Immunoglobulin (IVIG)
Takeda, Takeda Development Center Americas, Inc.
Mucopolysaccharidosis (MPS), Hunter Syndrome
07/28
07/28
NCT06045754: A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

Recruiting
4
150
Canada, US
Vedolizumab, Entyvio, Adalimumab, Humira, Ustekinumab, Stelara
Takeda
Crohn's Disease
06/27
06/27
NCT06095128: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Recruiting
4
65
Canada, US
Vedolizumab, Entyvio, MLN0002, Tofacitinib, Xeljanz, CP-690, CP-550
Takeda
Ulcerative Colitis
07/27
07/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT04840667 / 2018-004689-32: A Study of Replagal in Treatment-naïve Adults With Fabry Disease

Terminated
3
17
Europe, Canada
REPLAGAL, SHP675
Shire
Fabry Disease
12/22
12/22
NCT04444895 / 2019-004823-20: A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Completed
3
73
Europe, Canada, Japan, US
Lanadelumab, DX-2930, SHP643, TAK-743
Shire, Takeda Development Center Americas, Inc.
Angioedema
05/23
05/23
NCT03927027: Axillary Reverse Mapping in Preventing Lymphedema in Patients with Breast Cancer Undergoing Axillary Lymph Node Dissection

Active, not recruiting
3
534
US
Isosulfan Blue, Axillary Lymph Node Dissection, ALND, axillary dissection, Mapping, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
11/26
01/27
NRG-BR003, NCT02488967: Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting
3
782
Canada, US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
10/26
10/26
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
52
Europe, Japan, US
TAK-755, rADAMTS13, SHP-655, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
SWOG-S1600, NCT03757949: Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery

Active, not recruiting
3
203
US
Laboratory Biomarker Analysis, Nutritional Intervention, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
SWOG Cancer Research Network, National Cancer Institute (NCI)
Bladder Carcinoma
01/24
01/27
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
3
206
Canada, US
Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS)
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology
Brain Metastases
06/27
12/27
NCT03879135 / 2018-003453-16: A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

Completed
3
38
Europe, US, RoW
rVWF, Vonvendi, Vonicog alfa, rFVIII, Octocog alfa, ADVATE
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Von Willebrand Disease (VWD)
01/25
01/25
 

Download Options